WO2001095874A3 - Highly efficient delivery of a large therapeutic mass aerosol - Google Patents

Highly efficient delivery of a large therapeutic mass aerosol Download PDF

Info

Publication number
WO2001095874A3
WO2001095874A3 PCT/US2001/018491 US0118491W WO0195874A3 WO 2001095874 A3 WO2001095874 A3 WO 2001095874A3 US 0118491 W US0118491 W US 0118491W WO 0195874 A3 WO0195874 A3 WO 0195874A3
Authority
WO
WIPO (PCT)
Prior art keywords
particles
agent
highly efficient
efficient delivery
large therapeutic
Prior art date
Application number
PCT/US2001/018491
Other languages
French (fr)
Other versions
WO2001095874A2 (en
Inventor
David A Edwards
Richard P Batycky
Lloyd Johnston
Original Assignee
Advanced Inhalation Res Inc
David A Edwards
Richard P Batycky
Lloyd Johnston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24365965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001095874(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA002412561A priority Critical patent/CA2412561C/en
Priority to PL36028701A priority patent/PL360287A1/en
Priority to SI200130734T priority patent/SI1296663T1/en
Priority to KR1020027016748A priority patent/KR100697479B1/en
Priority to AU7536801A priority patent/AU7536801A/en
Priority to DE60127407T priority patent/DE60127407T2/en
Priority to NZ523254A priority patent/NZ523254A/en
Application filed by Advanced Inhalation Res Inc, David A Edwards, Richard P Batycky, Lloyd Johnston filed Critical Advanced Inhalation Res Inc
Priority to DK01942072T priority patent/DK1296663T3/en
Priority to AU2001275368A priority patent/AU2001275368B2/en
Priority to MXPA02012023A priority patent/MXPA02012023A/en
Priority to IL15328101A priority patent/IL153281A0/en
Priority to EP01942072A priority patent/EP1296663B1/en
Priority to JP2002510053A priority patent/JP2004503482A/en
Publication of WO2001095874A2 publication Critical patent/WO2001095874A2/en
Priority to NO20025873A priority patent/NO20025873L/en
Publication of WO2001095874A3 publication Critical patent/WO2001095874A3/en
Priority to HK03103294A priority patent/HK1051139A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Abstract

A method for delivering an agent to the pulmonary system, in a single, breath-activated step or a single breath, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g/cm3 and deliver at least about 50 % of the mass of particles. The particles are capable of carrying agents. The agent is: 1) part of the spray-drying pre-mixture and thereby incorporated into the particles; 2) added to separately-prepared particles so that the agent is in chemical association with the particles; or 3) blended so that the agent is mixed with, and co-delivered with the particles. Respirable compositions comprising carrier particles having a tap density of less than 0.4 g/cm3 and a composition comprising an agent are also disclosed. Methods of delivering these respirable compositions are also included.
PCT/US2001/018491 2000-06-09 2001-06-08 Highly efficient delivery of a large therapeutic mass aerosol WO2001095874A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
DK01942072T DK1296663T3 (en) 2000-06-09 2001-06-08 Very effective delivery of an aerosol with great therapeutic mass
AU2001275368A AU2001275368B2 (en) 2000-06-09 2001-06-08 Highly efficient delivery of a large therapeutic mass aerosol
PL36028701A PL360287A1 (en) 2000-06-09 2001-06-08 Highly efficient delivery of a large therapeutic mass aerosol
MXPA02012023A MXPA02012023A (en) 2000-06-09 2001-06-08 Highly efficient delivery of a large therapeutic mass aerosol.
AU7536801A AU7536801A (en) 2000-06-09 2001-06-08 Highly efficient delivery of a large therapeutic mass aerosol
DE60127407T DE60127407T2 (en) 2000-06-09 2001-06-08 HIGH-ACTIVE ADMINISTRATION OF AEROSOL WITH HIGH THERAPEUTIC MASS
NZ523254A NZ523254A (en) 2000-06-09 2001-06-08 Method of delivering a large therapeutic mass aerosol to the pulmonary system
CA002412561A CA2412561C (en) 2000-06-09 2001-06-08 Highly efficient delivery of a large therapeutic mass aerosol
JP2002510053A JP2004503482A (en) 2000-06-09 2001-06-08 Highly efficient delivery of large therapeutic mass aerosols
SI200130734T SI1296663T1 (en) 2000-06-09 2001-06-08 Highly efficient delivery of a large therapeutic mass aerosol
KR1020027016748A KR100697479B1 (en) 2000-06-09 2001-06-08 Highly efficient delivery of a large therapeutic mass aerosol
IL15328101A IL153281A0 (en) 2000-06-09 2001-06-08 Highly efficient delivery of a large therapeutic mass aerosol
EP01942072A EP1296663B1 (en) 2000-06-09 2001-06-08 Highly efficient delivery of a large therapeutic mass aerosol
NO20025873A NO20025873L (en) 2000-06-09 2002-12-06 Very effective delivery of a large therapeutic amount of aerosol
HK03103294A HK1051139A1 (en) 2000-06-09 2003-05-12 Highly efficient delivery of a large therapeutic mass aerosol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/591,307 2000-06-09
US09/591,307 US6858199B1 (en) 2000-06-09 2000-06-09 High efficient delivery of a large therapeutic mass aerosol

Publications (2)

Publication Number Publication Date
WO2001095874A2 WO2001095874A2 (en) 2001-12-20
WO2001095874A3 true WO2001095874A3 (en) 2003-01-16

Family

ID=24365965

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/018491 WO2001095874A2 (en) 2000-06-09 2001-06-08 Highly efficient delivery of a large therapeutic mass aerosol

Country Status (21)

Country Link
US (6) US6858199B1 (en)
EP (2) EP1296663B1 (en)
JP (2) JP2004503482A (en)
KR (1) KR100697479B1 (en)
CN (1) CN100589796C (en)
AT (1) ATE357222T1 (en)
AU (2) AU2001275368B2 (en)
CA (1) CA2412561C (en)
DE (1) DE60127407T2 (en)
DK (1) DK1296663T3 (en)
ES (1) ES2283417T3 (en)
HK (1) HK1051139A1 (en)
IL (1) IL153281A0 (en)
MX (1) MXPA02012023A (en)
NO (1) NO20025873L (en)
NZ (1) NZ523254A (en)
PL (1) PL360287A1 (en)
PT (1) PT1296663E (en)
RU (1) RU2275900C2 (en)
SI (1) SI1296663T1 (en)
WO (1) WO2001095874A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US8992983B2 (en) 2010-08-30 2015-03-31 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US9421166B2 (en) 2001-12-19 2016-08-23 Novartis Ag Pulmonary delivery of aminoglycoside
US9433576B2 (en) 2010-09-29 2016-09-06 Pulmatrix, Inc. Cationic dry powders
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6749835B1 (en) * 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2002032396A2 (en) * 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Lipid-protein-sugar particles for delivery of nucleic acids
AU2002316574B2 (en) * 2002-03-15 2008-05-01 Brandeis University Central airway administration for systemic delivery of therapeutics
WO2003079992A2 (en) * 2002-03-20 2003-10-02 Advanced Inhalation Research, Inc. Pulmonary delivery for levodopa
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
ES2718455T3 (en) 2002-03-20 2019-07-02 Civitas Therapeutics Inc Inhaled sustained therapeutic formulations
ES2300568T3 (en) 2002-03-20 2008-06-16 Mannkind Corporation INHALATION APPARATUS
US6930137B2 (en) * 2002-05-31 2005-08-16 Fina Technology, Inc. Method of improving blown film processing performance and physical properties
SI1531794T1 (en) * 2002-06-28 2017-12-29 Civitas Therapeteutics, Inc. Inhalable epinephrine
AU2003232081B2 (en) * 2002-07-03 2009-02-05 Brandeis University Central airway administration for systemic delivery of therapeutics
US6966990B2 (en) * 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
RU2364400C2 (en) * 2003-04-14 2009-08-20 Вектура Лтд Pharmaceutical compositions
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
DE10317461A1 (en) * 2003-04-16 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Preparing microparticles labeled with technetium, useful as powders for inhalation, e.g. to study deposition of pharmaceuticals, such as anticholinergic agents, involves incubation with solution of technetium salt
GB0313604D0 (en) * 2003-06-12 2003-07-16 Britannia Pharmaceuticals Ltd Delivery device for powdered medicament
ES2872350T3 (en) 2003-06-13 2021-11-02 Civitas Therapeutics Inc Low Dose Pharmaceutical Powders For Inhalation
EP1663159A4 (en) * 2003-09-10 2010-06-09 Map Pharmaceuticals Inc Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
WO2005077338A1 (en) * 2004-02-10 2005-08-25 Advanced Inhalation Research, Inc. Particles for inhalation rapid release properties
CN101098678A (en) * 2004-04-23 2008-01-02 锡德克斯公司 Dpi formulation containing sulfoalkyl ether cyclodextrin
MX2007001903A (en) 2004-08-20 2007-08-02 Mannkind Corp Catalysis of diketopiperazine synthesis.
KR101306384B1 (en) 2004-08-23 2013-09-09 맨카인드 코포레이션 Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
SE0402345L (en) * 2004-09-24 2006-03-25 Mederio Ag Measured drug dose
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060134009A1 (en) * 2004-12-16 2006-06-22 Daniel Deaver Low dose corticosteroid powders for inhalation
EP2402001A1 (en) * 2005-05-18 2012-01-04 Pulmatrix, Inc. Formulations for alteration of biophysical properties of mucosal lining
RU2008108510A (en) * 2005-08-11 2009-09-20 Президент Энд Феллоуз Гарвард Колледж (Us) METHODS AND COMPOSITIONS OF DRIED CELL FORMS
JP5465878B2 (en) 2005-09-14 2014-04-09 マンカインド コーポレイション Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20070123449A1 (en) * 2005-11-01 2007-05-31 Advanced Inhalation Research, Inc. High load particles for inhalation having rapid release properties
WO2009074634A2 (en) * 2007-12-13 2009-06-18 Glaxo Group Limited Compositions for pulmonary delivery
CN104383546B (en) 2006-02-22 2021-03-02 曼金德公司 Method for improving the pharmaceutical properties of microparticles comprising diketopiperazines and an active agent
GB0616299D0 (en) * 2006-08-16 2006-09-27 Cambridge Consultants Drug Capsules for dry power inhalers
EP2086617A4 (en) 2006-10-26 2013-11-20 Next Breath Llc Phospholipid-based inhalation system
US20080260852A1 (en) * 2007-01-23 2008-10-23 Ferro Pfanstiehl Laboratories, Inc. Supercritical fluid extraction produced by in-line homogenization
US7745566B2 (en) * 2007-01-23 2010-06-29 Ferro Corporation Methods for the purification of polymers
KR20090129998A (en) 2007-02-11 2009-12-17 맵 파마슈티컬스, 인코포레이티드 Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
JP2010527914A (en) * 2007-04-26 2010-08-19 クォーク ファーマシューティカルズ インコーポレーティッド Therapeutic delivery of inhibitory nucleic acid molecules to the respiratory system
EP2219613A1 (en) * 2007-10-26 2010-08-25 Università degli Studi di Parma Compositions in powder form made of soft agglomerates of a micronized drug and of a two-components excipient, and process for their preparation
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
WO2009082343A1 (en) * 2007-12-20 2009-07-02 Astrazeneca Ab Dispenser and method for entraining powder in an airflow 537
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN104689432B (en) 2008-06-13 2018-07-06 曼金德公司 Diskus and the system for drug conveying
JP5479465B2 (en) 2008-06-20 2014-04-23 マンカインド コーポレイション Interactive device and method for profiling inhalation efforts in real time
RU2508093C2 (en) * 2008-07-01 2014-02-27 Нитто Денко Корпорейшн Pharmaceutical composition containing coated microparticles
EP2328556A4 (en) * 2008-07-30 2013-11-20 Stc Unm Formulations containing large-size carrier particles for dry powder inhalation aerosols
TWI494123B (en) 2008-08-11 2015-08-01 Mannkind Corp Use of ultrarapid acting insulin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2753645C (en) 2009-02-27 2016-07-26 Pari Pharma Gmbh Method for operating an aerosol inhalation device and aerosol inhalation device
PL2405963T3 (en) 2009-03-11 2014-04-30 Mannkind Corp Apparatus, system and method for measuring resistance of an inhaler
JP5671001B2 (en) 2009-03-26 2015-02-18 パルマトリックス，インコーポレイテッド Dry powder formulation and method for treating lung disease
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
EP2440184B1 (en) 2009-06-12 2023-04-05 MannKind Corporation Diketopiperazine microparticles with defined specific surface areas
WO2010151804A1 (en) * 2009-06-26 2010-12-29 Map Pharmaceuticals, Inc. Administration of dihydroergotamine mesylate particles using a metered dose inhaler
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
EP2380618A1 (en) * 2010-04-26 2011-10-26 PARI Pharma GmbH Operating method for an aerosol delivery device and aerosol delivery device
RU2571331C1 (en) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Systems and methods for dry powder drug delivery
MX354828B (en) 2010-09-29 2018-03-22 Pulmatrix Operating Co Inc Monovalent metal cation dry powders for inhalation.
DK2694402T3 (en) 2011-04-01 2017-07-03 Mannkind Corp BLISTER PACKAGE FOR PHARMACEUTICAL CYLINDER AMPULS
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
PT106094A (en) 2012-01-13 2013-07-15 Hovione Farmaciencia S A ADMINISTRATION BY INHALATION OF FORMULATIONS WITH HIGH DOSE
CN107596518B (en) 2012-02-29 2021-04-23 普马特里克斯营业公司 Inhalable dry powder
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
RU2495682C1 (en) * 2012-07-12 2013-10-20 Дарья Сергеевна Петренко Method for drug delivery in treating or preventing tobacco smoking and/or respiratory diseases
EP2705838A1 (en) * 2012-09-06 2014-03-12 Xspray Microparticles Ab Tiotropium preparations
MX2021014782A (en) 2012-10-22 2023-03-23 Civitas Therapeutics Inc Levodopa formulations for rapid relief of parkinson's disease.
WO2014066206A1 (en) * 2012-10-22 2014-05-01 Civitas Therapeutics , Inc. Reducing inter-patient variability of levodopa plasma concentrations
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
US11052202B2 (en) * 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
MX2015012529A (en) * 2013-03-14 2016-07-05 Novartis Ag Deamorphization of spray-dried formulations via spray-blending.
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
CN105473133A (en) 2013-04-30 2016-04-06 欧缇托匹克公司 Dry powder formulations and methods of use
BR112016000937A8 (en) 2013-07-18 2021-06-22 Mannkind Corp dry powder pharmaceutical formulations, method for making a dry powder formulation and use of a dry powder pharmaceutical formulation
JP2016530930A (en) 2013-08-05 2016-10-06 マンカインド コーポレイション Ventilation device and method
CA2977083A1 (en) 2014-02-20 2015-08-27 Kambiz Yadidi Dry powder formulations for inhalation
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US20170296498A1 (en) 2014-04-21 2017-10-19 Civitas Therapeutics, Inc. Rapid Relief of Motor Fluctuations in Parkinson's Disease
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
MA40910A (en) 2014-11-07 2017-09-12 Civitas Therapeutics Inc RAPAMYCIN POWDERS FOR PULMONARY ADMINISTRATION
RU2750163C2 (en) 2015-06-04 2021-06-22 Крититек, Инк. Taxan particles and their application
JP2018524346A (en) 2015-07-02 2018-08-30 サイヴィタス セラピューティックス，インコーポレイテッド Triptan powder for pulmonary delivery
JP7077219B2 (en) * 2015-09-09 2022-05-30 ノバルティス アーゲー Targeted delivery of spray-dried product to the lungs
RU2737934C2 (en) 2016-04-04 2020-12-07 Крититек, Инк. Methods of treating solid tumors
AU2017261317A1 (en) 2016-05-05 2018-12-13 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
JP2020510002A (en) * 2017-03-07 2020-04-02 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム Inhalable nicotine formulations and methods of making and using the same
SG10201913649TA (en) 2017-06-09 2020-03-30 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
CA3063436A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
CN111278436A (en) 2017-10-03 2020-06-12 克里蒂泰克公司 Local delivery of anti-tumor particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
AU2020236689A1 (en) * 2019-03-08 2021-09-02 Chromaflo Technologies Europe B.V. Solid colorant dispensing unit and tinting machine comprising the same
CN113318097A (en) * 2021-04-29 2021-08-31 珠海瑞思普利医药科技有限公司 Powder inhalation for resisting idiopathic pulmonary fibrosis and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1999066903A2 (en) * 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
WO2000010541A1 (en) * 1998-08-25 2000-03-02 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
WO2000033811A2 (en) * 1998-12-09 2000-06-15 Vectura Limited Improvements in or relating to powders
WO2001013893A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
EP0072046B1 (en) * 1981-07-24 1986-01-15 FISONS plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
US5260306A (en) 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
IT1228459B (en) 1989-02-23 1991-06-19 Phidea S R L INHALER WITH REGULAR AND COMPLETE EMPTYING OF THE CAPSULE.
US5174988A (en) 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5304125A (en) 1990-10-05 1994-04-19 The University Of North Carolina Apparatus for administering solid particulate aerosols to the lungs
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
SE9203743D0 (en) 1992-12-11 1992-12-11 Astra Ab EFFICIENT USE
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
GB9313650D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
MX9603936A (en) * 1994-03-07 1997-05-31 Inhale Therapeutic Syst Methods and compositions for pulmonary delivery of insulin.
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5641510A (en) 1994-07-01 1997-06-24 Genentech, Inc. Method for treating capsules used for drug storage
MX9702357A (en) 1994-09-29 1997-06-28 Andaris Ltd Spray-dried microparticles as therapeutic vehicles.
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
WO1996032096A1 (en) 1995-04-14 1996-10-17 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
GB9621825D0 (en) 1996-10-19 1996-12-11 Andaris Ltd Microparticles and their use as therapeutic vehicles
JP2001517692A (en) 1997-09-29 2001-10-09 インヘール セラピューティック システムズ， インコーポレイテッド Stabilized preparation for use in a nebulizer
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20010007853A1 (en) * 1998-01-08 2001-07-12 Dimarchi Richard Dennis Method for administering monomeric insulin analogs
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
ATE313318T1 (en) * 1999-10-29 2006-01-15 Nektar Therapeutics DRY POWDER COMPOSITIONS WITH IMPROVED DISPERSITY
WO2001051030A1 (en) 2000-01-10 2001-07-19 Dura Pharmaceuticals, Inc. Pharmaceutical formulation and method for pulmonary and oral delivery
US6848197B2 (en) * 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1999066903A2 (en) * 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
WO2000010541A1 (en) * 1998-08-25 2000-03-02 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
WO2000033811A2 (en) * 1998-12-09 2000-06-15 Vectura Limited Improvements in or relating to powders
WO2001013893A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANDERSON S D ET AL: "A NEW METHOD FOR BRONCHIAL-PROVOCATION TESTING IN ASTHMATIC SUBJECTS USING A DRY POWDER OF MANNITOL", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, AMERICAN LUNG ASSOCIATION, NEW YORK, NY, US, vol. 156, no. 3 PART 1, 1997, pages 758 - 765, XP002177457, ISSN: 1073-449X *
ANDERSON S D ET AL: "The effect of inhaling a dry powder of sodium chloride on the airways of asthmatic subjects", EUROPEAN RESPIRATORY JOURNAL, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 10, no. 11, November 1997 (1997-11-01), pages 2465 - 2473, XP002120358, ISSN: 0903-1936 *
BEN-JEBRIA A ET AL: "LARGE POROUS PARTICLES FOR SUSTAINED PROTECTION FROM CARBACHOL- INDUCED BRONCHOCONSTRICTION IN GUINEA PIGS", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 16, no. 4, April 1999 (1999-04-01), pages 555 - 561, XP000856767, ISSN: 0724-8741 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US9439862B2 (en) 2000-05-10 2016-09-13 Novartis Ag Phospholipid-based powders for drug delivery
US9421166B2 (en) 2001-12-19 2016-08-23 Novartis Ag Pulmonary delivery of aminoglycoside
US8992983B2 (en) 2010-08-30 2015-03-31 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US9233158B2 (en) 2010-08-30 2016-01-12 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US9433576B2 (en) 2010-09-29 2016-09-06 Pulmatrix, Inc. Cationic dry powders

Also Published As

Publication number Publication date
EP1767196A3 (en) 2009-02-25
US20040076589A1 (en) 2004-04-22
WO2001095874A2 (en) 2001-12-20
AU2001275368B2 (en) 2005-10-20
ATE357222T1 (en) 2007-04-15
NZ523254A (en) 2004-07-30
US8628754B2 (en) 2014-01-14
KR20030063117A (en) 2003-07-28
US20020035993A1 (en) 2002-03-28
MXPA02012023A (en) 2004-08-19
DK1296663T3 (en) 2007-07-30
RU2275900C2 (en) 2006-05-10
DE60127407D1 (en) 2007-05-03
EP1296663A2 (en) 2003-04-02
JP2009019047A (en) 2009-01-29
US20120093893A1 (en) 2012-04-19
EP1296663B1 (en) 2007-03-21
PL360287A1 (en) 2004-09-06
NO20025873D0 (en) 2002-12-06
US6921528B2 (en) 2005-07-26
DE60127407T2 (en) 2007-11-29
US20090068274A1 (en) 2009-03-12
US6858199B1 (en) 2005-02-22
HK1051139A1 (en) 2003-07-25
CA2412561A1 (en) 2001-12-20
CN100589796C (en) 2010-02-17
CA2412561C (en) 2009-05-12
AU7536801A (en) 2001-12-24
JP2004503482A (en) 2004-02-05
ES2283417T3 (en) 2007-11-01
US20140178476A1 (en) 2014-06-26
EP1767196A2 (en) 2007-03-28
PT1296663E (en) 2007-06-22
US7556798B2 (en) 2009-07-07
SI1296663T1 (en) 2007-08-31
NO20025873L (en) 2003-02-06
IL153281A0 (en) 2003-07-06
KR100697479B1 (en) 2007-03-20
CN1441670A (en) 2003-09-10

Similar Documents

Publication Publication Date Title
WO2001095874A3 (en) Highly efficient delivery of a large therapeutic mass aerosol
BG104720A (en) Aerosolized active agent delivery
WO2004112702A3 (en) Low dose pharmaceutical powders for inhalation
CA2304819A1 (en) Perforated microparticles and methods of use
IL152306A0 (en) Improvements in or relating to formulations for use in inhaler devices
JO2430B1 (en) Pharmaceuticall Formulations for Dry Powder Inhalers in the form of Hard- Pellets
EA200100338A1 (en) METHOD AND DEVICE FOR INTRODUCTION OF EXISTING SUBSTANCE IN THE FORM OF AEROSOL IN LUNG PATIENT
IS4179A (en) Inhaled polypeptide formulation composition which also contains an enhancer compound
JO3102B1 (en) Pharmaceutical formulations for dry powder inhalers comprising a low- dosage strength active ingredient
TNSN05047A1 (en) Inhalation composition
MXPA05009629A (en) Trospium containing compositions.
WO2004012653A3 (en) Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof
EP1599209A4 (en) Inhalation composition
PL365736A1 (en) Bimodal dry powder formulation for inhalation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 153281

Country of ref document: IL

Ref document number: 2001942072

Country of ref document: EP

WWE Wipo information: entry into national phase

Country of ref document: MX

Ref document number: PA/a/2002/012023

WWE Wipo information: entry into national phase

Ref document number: 2412561

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2002 510053

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020027016748

Country of ref document: KR

Ref document number: 2001275368

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 523254

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2002134467

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWE Wipo information: entry into national phase

Ref document number: 018125336

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001942072

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020027016748

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 523254

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 523254

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001275368

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2001942072

Country of ref document: EP